Annuncio
relativo a: Jerry McMahonFind Their Age, Phone Number & Address. See Their Online Pics and Profiles.
Risultati di ricerca
7 set 2022 · STORM’s first-in-class clinical candidate STC-15, an orally-bioavailable, highly selective METTL3 inhibitor, is on schedule to start initial clinical studies in solid tumors in 2022 and will be the first first-ever RME inhibitor molecule to enter clinical development.
Jerry McMahon, PhD Chief Executive Officer & President Jerry has over 30 years of biotechnology leadership, scientific innovation, creative deal-making, and financing experience.
View Jerry McMahon’s profile on LinkedIn, a professional community of 1 billion members. Dr. McMahon brings more than 30 years of exceptional biotechnology leadership, scientific…
- 500+
- STORM Therapeutics
- Yorktown High School
- San Francisco, California, United States
7 set 2022 · Industry veteran to lead STORM as it transitions into a clinical-stage company with a pipeline of products targeting RNA modifying enzymes. Dr. McMahon Joins as Board Director. CAMBRIDGE,...
7 set 2022 · 7 September 2022, Cambridge, UK: STORM Therapeutics Ltd. (STORM), the biotechnology company discovering and developing novel small molecule therapies targeting RNA modification enzymes for oncology and other diseases, today announced the appointment of Dr. Gerald (Jerry) McMahon as President and Chief Executive Officer and Board ...
Jerry McMahon. CEO, Storm Therapeutics. Jerry McMahon has over 30 years of biotechnology leadership, scientific innovation, deal-making, and financing experience.
Jerry McMahon, PhD Chief Executive Officer & President Jerry has over 30 years of biotechnology leadership, scientific innovation, creative deal-making, and financing experience.
Annuncio
relativo a: Jerry McMahonspokeo.com è stato visitato da più di 100.000 utenti nell’ultimo mese
Find Their Age, Phone Number & Address. See Their Online Pics and Profiles.
